comprehensive -WSS

comprehensive

author：knowledge 2025-09-30 22:27:19 - browse：198

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： How state and local governments are sidelining science

WSS

STAT Virtual Event: JPM Recap, Live!

At JPM 2024, hospital systems pitch financial strength to investors

Allen Institute goes after foundational questions, CEO Costa says

Boston Scientific acquires urology company Axonics for $3.7 billion

FDA reorg will put new emphasis on investigations, sources say

What health policies could hitch a ride on a spending bill?

focus

comprehensive

leisure time

Medicare details structure of new drug price negotiation program

What is STAT's opinion section for?

At least 13 dead in Texas as scorching temps continue

Life science postdocs should get big pay hike, NIH panel says

As demand for Covid shots wanes, Moderna seeks its next success

White House drug czar issues call for 'recovery

Anesthesiologist group: stop taking Ozempic before surgery

STAT Virtual Event: JPM Recap, Live!

Guidelines to prevent youth baseball injuries need more muscle

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

explore

Ventyx halts psoriasis drug development after lackluster trial results

Ascension's ugly legal battle over care for poor patients in Texas

Nonprofit, backed by Microsoft, to certify AI tools in health care

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

医院占地30亩，分两期建设，一期建设国际医学中心，二期建设康养中心。

Carbon Health diabetes program, a test of data

hotspot

hotspot

focus

leisure time